
T-Cort55 mcg/spr
Opsonin Pharma Ltd.
Established / Approved Uses Topical (cream/ointment/lotion): Triamcinolone Acetonide is indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses and more.
In allergic rhinitis, Triamcinolone Acetonide nasal spray is often used together with, or as an alternative to, oral antihistamines depending on symptom severity. Intra-articular Triamcinolone Acetonide is used as an adjunct to rest, physiotherapy, and other standard measures for localized joint inflammation, not as monotherapy for the underlying disease.
Not all forms of Triamcinolone Acetonide are marketed for every indication above in every country; use only the form and indication prescribed by your physician.
Apply a thin layer to the affected skin area 2–3 times daily (or as directed). Gently rub in. Occlusive dressings are not routinely recommended and should only be used under medical supervision for limited periods due to increased risk of systemic absorption. Avoid use on the face, groin, or axillae for prolonged periods.
| Population | Dose |
|---|---|
| Adults and children ≥12 years | 2 sprays (110 mcg total) in each nostril once daily (max 220 mcg/day); may reduce to 1 spray/nostril once symptoms controlled |
| Children 2–11 years | 1 spray (55 mcg) in each nostril once daily |
Apply a small amount (approximately 1/4 inch) to the lesion without rubbing, preferably at bedtime for prolonged overnight contact, and 2–3 times daily after meals if needed. Reassess if no improvement within 7 days.
| Use | Typical adult dose |
|---|---|
| Intramuscular (systemic effect) | Initially 60 mg by deep IM injection into the gluteal muscle; subsequent doses adjusted (commonly 40–80 mg) based on patient response and duration of relief |
| Intra-articular (large joints, e.g., knee) | 5–15 mg per joint |
| Intra-articular (small joints) | 2.5–5 mg per joint |
| Intralesional (dermatologic lesions) | Up to 1 mg per injection site, depending on lesion |
Pediatric injectable dosing is generally weight-based (approximately 0.03–0.2 mg/kg/day IM, or as directed by the treating physician) and should be individualized; consult a pediatric specialist.
The injectable suspension is for intramuscular, intra-articular, or intralesional use only. It must never be given intravenously, and must not be given by the epidural or intrathecal route (see Precautions and Warnings).
Common: burning, itching, irritation, dryness at the application site. Less common: folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, skin atrophy, striae, telangiectasia, perioral dermatitis, and allergic contact dermatitis, particularly with prolonged or occlusive use.
Headache, nasal irritation/dryness, epistaxis (nosebleed), sore throat, and cough. Rarely, nasal septal perforation with prolonged use.
Local burning, stinging, dryness, blistering or peeling of oral mucosa; secondary oral fungal infection (candidiasis) with prolonged use.
Injection-site reactions (pain, atrophy, hypopigmentation), and — particularly with repeated or systemic-dose use — fluid retention, hypertension, hyperglycemia, mood/behavioral changes, increased susceptibility to infection, menstrual irregularities, and (with long-term use) osteoporosis, cushingoid features, and adrenal suppression.
Triamcinolone Acetonide is contraindicated in:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.